Miguel Elizondo, MD
Family Medicine · Corpus Christi, TXNPI 1326667965
Payments from drug & device makers
Across 282 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$867
- Novo Nordisk$784
- AstraZeneca$397
- Bayer$321
- AbbVie$310
- Dexcom, Inc.$292
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,85998%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 71 | $867 |
| Novo Nordisk | 42 | $784 |
| AstraZeneca | 20 | $397 |
| Bayer | 14 | $321 |
| AbbVie | 19 | $310 |
| Dexcom, Inc. | 17 | $292 |
| Amgen | 13 | $280 |
| GSK | 15 | $266 |
| Pfizer | 10 | $189 |
| Otsuka America Pharmaceutical, Inc. | 5 | $138 |
| Ardelyx, Inc. | 6 | $120 |
| Exact Sciences | 6 | $106 |
| Merck | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| Boehringer Ingelheim | 5 | $91 |
| Scpharmaceuticals Inc. | 3 | $73 |
| Lundbeck LLC | 3 | $65 |
| Astellas Pharma US Inc | 1 | $65 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 2 | $38 |
| Corcept Therapeutics | 2 | $36 |
| Integra Lifesciences Corporation | 1 | $31 |
| Phadia US Inc. | 2 | $31 |
| Shield Therapeutics Inc | 2 | $28 |
| Sumitomo Pharma America, Inc. | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Abbott | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,951 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 286 | $354,390 |
| MounjaroTirzepatide | 228 | $291,295 |
| JardianceEmpagliflozin | 177 | $154,674 |
| TrulicityDulaglutide | 76 | $102,658 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 124 | $91,863 |
| RybelsusSemaglutide | 65 | $84,555 |
| FarxigaDapagliflozin Propanediol | 104 | $82,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $53,171 |
| EliquisApixaban | 68 | $52,164 |
| JanuviaSitagliptin Phosphate | 39 | $40,376 |
| VraylarCariprazine Hcl | 27 | $38,355 |
| LinzessLinaclotide | 52 | $37,916 |
| VascepaIcosapent Ethyl | 62 | $31,503 |
| TrintellixVortioxetine Hydrobromide | 55 | $31,404 |
| EntrestoSacubitril/Valsartan | 23 | $31,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $784 | $438,944351 claims |
| Lilly USA, LLCMounjaro, Trulicity | $867 | $393,953304 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $91 | $177,087206 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $397 | $174,141228 claims |
| AbbVieVraylar, Linzess, Ubrelvy | $310 | $89,54891 claims |
| GSKTrelegy Ellipta | $266 | $53,17175 claims |
| PfizerEliquis | $189 | $52,16468 claims |
| MerckJanuvia, Janumet Xr | $104 | $47,29551 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $93 | $31,40455 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $25,04453 claims |
| AmgenProlia | $280 | $23,18313 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $38 | $15,04231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Corpus Christi
- Michael WinnieCorpus Christi$3.9M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.